In the present work, we found that Gal-3 in melanocytes and melanoma cells decreased autophagy activity and it also regulated the cell fate after the treatment with the mutated BRAF inhibitor, vemurafenib (PLX-4032 or PLX). Here, BRAF is linked to melanoma.